Ethical considerations in studying drug safety - The institute of medicine report

New England Journal of Medicine

Volumn 367, Issue 10, 2012, Pages 959-964

  Mello, Michelle M ^a   Goodman, Steven N ^b   Faden, Ruth R ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG LEGISLATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEART INFARCTION; HUMAN; INFORMED CONSENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESEARCH ETHICS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

EID: 84865684680     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMhle1207160     Document Type: Article

References (34)

1. Food and Drug Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823. (2007).
2. London AJ, Kimmelman J, Carlisle B. Research ethics: rethinking research ethics: the case of postmarketing trials. Science 2012;336:544-5.
3. ClinicalTrials.gov. Thiazolidinedione Intervention with Vitamin D Evaluation (TIDE). 2011 (http://clinicaltrials.gov/ct2/show/NCT00879970?term= NCT00879970&rank=1).
4. Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Institute of Medicine. Ethical and scientific issues in studying the safety of approved drugs. Washington, DC: National Academies Press, 2012 (http://www.iom.edu/Reports/2012/Ethical-and-Scientific-Issues-in-Studying-the- Safety-of- Approved-Drugs.aspx).
5. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. [Erratum, N Engl J Med 2007;357:100.] (Pubitemid 46919772)
6. Hamburg M. Letter to the honorable Charles E. Grassley. March 30, 2010 (http://online.wsj.com/public/resources/documents/Grassley.pdf).
7. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. (Pubitemid 47403104)
8. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. (Pubitemid 41416583)
9. Graham D, Gelperin K. Memorandum to Mary Parks, re: benefit-risk assessment of rosiglitazone vs. pioglitazone. October 7, 2008 (http://www.finance.senate.gov/newsroom/chairman/release/?id= bc56b552-efc5-4706-968d-f7032d5cd2e4).
10. Mahoney K. Advisory committee clinical briefing document: preliminary endocrine medical officer review of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) Trial, and update on cardiovascular safety information from large clinical trials of rosiglitazone. 2010 (http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM218493.pdf).
11. Baucus M, Grassley C. Letter to the honorable Margaret A. Hamburg, MD. February 18, 2010 (http://www.finance.senate.gov/newsroom/chairman/release/?id= bc56b552-efc5-4706-968d-f7032d5cd2e4).
12. Woodcock J. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). 2010 (memorandum) (http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf) .
13. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91.
14. Food and Drug Administration, Center for Drug Evaluation and Research. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. July 14, 2010 (transcript) (http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM222629.pdf).
15. Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Institute of Medicine. Ethical issues in studying the safety of approved drugs: a letter report. Washington, DC: National Academies Press, July 2010 (http://www.nap.edu/catalog.php?record-id=12948).
16. Committee on the Assessment of the U.S. Drug Safety System, Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. Washington, DC: National Academies Press, 2007 (http://www.iom.edu/ Reports/2006/The-Future-of-Drug-Safety-Promoting-and-Protecting-the-Health-of- the-Public.aspx).
17. U.S. Senate. Health, Education, Labor and Pension Committee. Food and Drug Administration Safety and Innovation Act (discussion draft), 112th Cong., 2d Sess. 2012 (http://www.help.senate.gov/imo/media/audio/KER12172.pdf).
18. Chen JY, Carter M. Bioethics and post-approval research in translational science. Am J Bioeth 2010;10:35-7.
19. Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA 2012 May 4 (Epub ahead of print).
20. Misbin RI. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes. Diabetes Care 2007;30:3141-4. (Pubitemid 350255264)
21. Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9(4):e1001201.
22. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5(11):e217. [Erratum, PloS Med 2009;6(1):e17.]
23. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010;31:773-6.
24. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-5. (Pubitemid 40548187)
25. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91. [Erratum, Circulation 2005;111:2274.] (Pubitemid 40470642)
26. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6. (Pubitemid 41697247)
27. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005;52:1968-78. (Pubitemid 40994317)
28. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8. N Engl J Med 2005;353:2813-4. (Pubitemid 43016825)
29. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
30. Kesselheim AS, Mello MM. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Health Aff (Millwood) 2007;26:483-91.
31. Krumholz H. The FDA is faster: now let's make it safer. Outcomes. Forbes.com. May 16, 2012 (http://blogs.forbes.com/harlankrumholz).
32. Punthakee Z, Bosch J, Dagenais G, et al. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia 2012;55:36-45.
33. Levine C. Has AIDS changed the ethics of human subjects research? Law Med Health Care 1988;16:167-73.
34. Food and Drug Administration. Guidance for industry: post-marketing studies and clinical trials - implementation of section 505(o)(3) of the federal Food, Drug, and Cosmetic Act. April 2011 (http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM172001.pdf).